摘要
目的探讨慢性阻塞性肺疾病(COPD)用噻托溴铵联合布地奈德福莫特罗治疗的效果。方法选取2019年1月~2020年1月宜春市人民医院收治的88例稳定期COPD患者,采用随机数字表法分为两组,每组各44例。对照组采用布地奈德福莫特罗治疗,观察组在对照组基础上加用噻托溴铵治疗。比较两组的临床疗效、肺功能、血清细胞因子水平及不良反应发生情况。结果观察组的总有效率(97.73%)高于对照组(79.55%),差异有统计学意义(P<0.05)。两组治疗前第1秒用力呼吸容积(FEV1)、用力肺活量(FVC)、FEV1/FVC、白介素-6(IL-6)、基质金属蛋白酶抑制因子-1(TIMP-1)和转化生长因子-β(TGF-β)比较,差异无统计学意义(P>0.05)。治疗3个月后,观察组的FEV1[(2.71±0.45)mL]、FVC[(3.11±0.39)mL]、FEV1/FVC[(72.34±6.55)%],高于对照组的(2.26±0.43)mL、(2.57±0.19)mL、(62.21±7.51)%;治疗3个月后,观察组的IL-6[(15.06±6.03)ng/ml]、TIMP-1[(120.25±32.82)ng/mL]、TGF-β[(79.54±9.24)ng/L],低于对照组的(21.68±7.41)ng/mL、(145.11±33.18)ng/mL、(87.25±9.72)ng/L,差异均有统计学意义(P<0.05)。两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论COPD患者使用噻托溴铵联合布地奈德福莫特罗治疗效果较好,能改善患者肺功能,降低炎性反应,且安全性较高,可作为COPD患者安全有效的治疗方式。
Objective To investigate the efficacy of Tiotropium Bromide combined with Budesonide Formoterol in the treatment of chronic obstructive pulmonary disease(COPD).Methods A total of 88 patients with stable COPD admitted to Yichun People′s Hospital from January 2019 to January 2020 were selected and divided into two groups according to random number table method,44 cases in each group.The control group was treated with Budesonide Formoterol,and the observation group was treated with Tiotropium Bromide on the basis of the control group.The clinical efficacy,pulmonary function and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was higher than that in the control group,the difference was statistically significant(P<0.05).Forced expiratory volumone second(FEV1),forced vital capacity(FVC),FEV1/FVC,interleukin-6(IL-6),tissue inhibitor of metalloproteinase-1(TIMP-1)and transforming growth factor-β(TGF-β)between two groups before treatment were compared,the differences had no statistically significant(P>0.05).After treatment 3 months,in the observation group,FEV1 was(2.71±0.45)mL,FVC was(3.11±0.39)mL,FEV1/FVC was(72.34±6.55)%,which were higher than those in the control of(2.26±0.43)mL,(2.57±0.19)mL,(62.21±7.51)%,after treatment 3 months,in the observation group,IL-6 was(15.06±6.03)ng/mL,TIMP-1 was(120.25±32.82)ng/mL,TGF-βwas(79.54±9.24)ng/L,which were lower than those in the control group of(21.68±7.41)ng/mL,(145.11±33.18)ng/mL,(87.25±9.72)ng/L,the differences were statistically significant(P<0.05).There was significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Tiotropium Bromide combined with Budesonide Formoterol is effective in the treatment of COPD.It can improve the lung function and has high safety.It can be used as a safe and effective treatment for COPD patients.
作者
朱俞俊
梁秋红
ZHU Yu-jun;LIANG Qiu-hong(Department of Respiratory,Yichun People′s Hospital,Jiangxi Province,Yichun336000,China;Department of Infection,the Second People′s Hospital of Yichun City,Jiangxi Province,Yichun336000,China)
出处
《中国当代医药》
2020年第32期55-57,61,共4页
China Modern Medicine
基金
江西省宜春市科技计划项目(JXYC2019KSC015)。
关键词
慢性阻塞性肺疾病
噻托溴铵
布地奈德福莫特罗
肺功能
不良反应
Chronic obstructive pulmonary disease
Tiotropium Bromide
Budesonide Formoterol
Lung function
Adverse reactions
作者简介
朱俞俊(1984-),男,江苏南通人,本科,主治医师,研究方向:呼吸内科。
